Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
NCT00185588Phase 2Completed
- Start
- Oct 2004
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vatalanib in pancreatic cancer (PC) (4 arms). Primary endpoint: Time-to-Treatment Failure at 12 months. Started Oct 2004; status: completed.
02
Drugs
vatalanib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00185588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185588.